Larry C. Lands, MD, PhD; Director, Pediatric Respiratory Medicine, Pediatric Cystic Fibrosis Clinic, and Pediatric Pulmonary Function Laboratory

Pulmonology; Pediatric Pulmonary Function Laboratory
Fun fact about me 

I have a comic book collection.

I love working with children and their families because 
I enjoy listening to all the giggling.

Hospital information

Academic appointments 

Professor, Department of Pediatrics, Faculty of Medicine, McGill University 

Other appointments 
  • Canadian Thoracic Society Chair Research Committee   
  • Cystic Fibrosis Canada Chair Scientific Advisory Council  
  • CF Canada’s clinical research network, CFCanACT, Executive Committee member and co-chair, protocol review committee 
  • Associate Editor, Paediatric Respiratory Reviews 
  • Associate Editor, Pediatric Pulmonology 



B.Sc., Mathematics Major, Biology Minor, McGill University; PhD, Medical Sciences, McMaster University

Medical Degree 

McGill University


Pediatrics, Montreal Children's Hospital


Pediatric Pulmonology, Montreal Children's Hospital


Research interests 

I conduct both clinical and translational research. We study lung function and exercise ability in children and adults living with conditions such as Cystic Fibrosis, Primary Ciliary Dyskinesia, obesity, and cancer and new ways to easily assess lung function in infants and children. In my bench laboratory we are developing inhaled nucleic acid and small molecule therapeutics using lipid nanoparticles to treat chronic lung diseases including inherited diseases such as Cystic Fibrosis and Primary Ciliary Dyskinesia and common lung conditions like asthma and COPD (chronic bronchitis and emphysema). We have a particular interest in controlling inflammation in these diseases.

Research foci 
  • Chronic lung disease
  • Inhaled nucleic acid and small molecule therapeutics
  • Exercise physiology
  • Oscillometry

Cystic Fibrosis (CF), Primary Ciliary Dyskinesia (PCD), asthma, lipid nanoparticles, RNA therapeutics, exercise, oscillometry, translational research

Selected publications 

Dauletbaev N, Cammisano M (S), Herscovitch K (S), Lands LC. Targeted stimulation of antiviral interferon-beta in airway epithelial cells and macrophages with minimal concomitant inflammation. J Immunol 195(6):2829-41, 2015. 

Dauletbaev N, Das M (S), Cammisano M (S), Koi C, Leigh R, Beaudoin T, Rousseau S, Lands LC. Viral load is high despite preserved interferon-beta response in rhinovirus-infected CF cells. PLoS ONE November 23; 10(11):e0143129. 2015.  

Mak, DYF, Sykes J, Stephenson AL, Lands LC.  The benefits of newborn screening for cystic fibrosis: The Canadian Experience. J CF 2016 May;15(3):302-8. 

Hebestreit H, Hulzebos EH, Schneiderman JE, Karila C, Boas SR, Kriemler S, Dwyer T, Sahlberg M, Urquhart DS, Lands LC, Ratjen F, Takken T, Varanistkaya L, Rücker V, Hebestreit A, Usemann J, Radtke T. Cardiopulmonary exercise testing provides additional prognostic information in cystic fibrosis. Am J Respir Crit Care Med 2019;199(8):987-995. 

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 Nov 7;381(19):1809-1819.